Influence of Indoleamine-2,3-Dioxygenase and Its Metabolite Kynurenine on γδ T Cell Cytotoxicity against Ductal Pancreatic Adenocarcinoma Cells

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment

(2019) Juliane Günther et al.   Frontiers in Immunology

TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells

(2019) Doaa Tawfik et al.   Frontiers in Immunology

Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma

(2019) Soudabeh Rad Pour et al.   Scientific Reports

Bispecific antibodies enhance tumor‐infiltrating T cell cytotoxicity against autologous HER‐2‐expressing high‐grade ovarian tumors

(2019) Hans‐Heinrich Oberg et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Chemotherapy accelerates immune-senescence and functional impairments of Vδ2pos T cells in elderly patients affected by liver metastatic colorectal cancer

(2019) Elena Bruni et al.   Journal for ImmunoTherapy of Cancer

Tumor-Repopulating Cells Induce PD-1 Expression in CD8 + T Cells by Transferring Kynurenine and AhR Activation

(2018) Yuying Liu et al.   CANCER CELL

Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation

(2018) Anna Capsomidis et al.   MOLECULAR THERAPY

Single cell analysis of kynurenine and System L amino acid transport in T cells

(2018) Linda V. Sinclair et al.   Nature Communications

Companies Scaling Back IDO1 Inhibitor Trials

(2018)   Cancer Discovery

γδ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion

(2018) Elena Lo Presti et al.   Frontiers in Immunology

How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive

(2018) Alessandro Poggi et al.   Frontiers in Immunology

Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond

(2018) Alexander J. Muller et al.   Seminars in Immunopathology

Corrigendum: How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive

(2018) Alessandro Poggi et al.   Frontiers in Immunology

Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer

(2018) Eric Fox et al.   Frontiers in Oncology

Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer

(2018) Emelie Rådestad et al.   OncoImmunology

The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy

(2017) Lieve Brochez et al.   EUROPEAN JOURNAL OF CANCER

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor

(2017) Benjamin J. Moyer et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

(2017) Christian Kellner et al.   TRANSFUSION MEDICINE AND HEMOTHERAPY

The Ambiguous Role of γδ T Lymphocytes in Antitumor Immunity

(2017) Guranda Chitadze et al.   TRENDS IN IMMUNOLOGY

Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer

(2017) S. Meraviglia et al.   OncoImmunology

IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population

(2017) Clément Barjon et al.   OncoImmunology

IFNγ Regulates Activated Vδ2+ T Cells through a Feedback Mechanism Mediated by Mesenchymal Stem Cells

(2017) Karoline Fechter et al.   PLoS One

γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

(2016) Donnele Daley et al.   CELL

CD69 controls the uptake of L-tryptophan through LAT1-CD98 and AhR-dependent secretion of IL-22 in psoriasis

(2016) Danay Cibrian et al.   NATURE IMMUNOLOGY

Erratum: CD69 controls the uptake of L-tryptophan through LAT1-CD98 and AhR-dependent secretion of IL-22 in psoriasis

(2016) Danay Cibrian et al.   NATURE IMMUNOLOGY

Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients

(2016) Hans-Heinrich Oberg et al.   PANCREATOLOGY

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

(2016) David H. Munn et al.   TRENDS IN IMMUNOLOGY

Epidemiology of pancreatic cancer

(2016) Milena Ilic et al.   WORLD JOURNAL OF GASTROENTEROLOGY

γδ T cell activation by bispecific antibodies

(2015) Hans-Heinrich Oberg et al.   CELLULAR IMMUNOLOGY

Bispecific antibodies

(2015) Roland E. Kontermann et al.   DRUG DISCOVERY TODAY

The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment

(2015) Johanna M Gostner et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The prognostic landscape of genes and infiltrating immune cells across human cancers

(2015) Andrew J Gentles et al.   NATURE MEDICINE

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors

(2015) Michael Platten et al.   Frontiers in Immunology

Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity

(2015) Daniel Gonnermann et al.   OncoImmunology

Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR

(2015) Ulrike M. Litzenburger et al.   Oncotarget

Novel Bispecific Antibodies Increase    T-Cell Cytotoxicity against Pancreatic Cancer Cells

(2014) H.-H. Oberg et al.   CANCER RESEARCH

Progression of Pancreatic Adenocarcinoma Is Significantly Impeded with a Combination of Vaccine and COX-2 Inhibition

(2014) P. Mukherjee et al.   JOURNAL OF IMMUNOLOGY

L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression

(2014) Evelin Grage-Griebenow et al.   Molecular Oncology

Comparative Characterization of Stroma Cells and Ductal Epithelium in Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma

(2014) Ole Helm et al.   PLoS One

Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy

(2014) Hans-Heinrich Oberg et al.   Frontiers in Immunology

Plasticity of γδ T Cells: Impact on the Anti-Tumor Response

(2014) Virginie Lafont et al.   Frontiers in Immunology

The stromal compartments in pancreatic cancer: Are there any therapeutic targets?

(2013) Serena Lunardi et al.   CANCER LETTERS

Changing T-cell enigma: Cancer killing or cancer control?

(2013) Thomas Wieder et al.   CELL CYCLE

Phenotype and regulation of immunosuppressive Vδ2-expressing γδ T cells

(2013) Christian Peters et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Activation of the IL-6R/Jak/Stat Pathway is Associated with a Poor Outcome in Resected Pancreatic Ductal Adenocarcinoma

(2013) Simon M. Denley et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Nucleotide Specificity of DNA Binding of the Aryl Hydrocarbon Receptor:ARNT Complex Is Unaffected by Ligand Structure

(2013) Danica E. DeGroot et al.   TOXICOLOGICAL SCIENCES

EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-κB activation

(2012) Helena Kiefel et al.   CARCINOGENESIS

Using an Ancient Tool for Igniting and Propagating Immune Tolerance: IDO as an Inducer and Amplifier of Regulatory T Cell Functions

(2012) F. Fallarino et al.   CURRENT MEDICINAL CHEMISTRY

Indoleamine 2,3-dioxygenase, Tregs and Cancer

(2012) D. H. Munn   CURRENT MEDICINAL CHEMISTRY

The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer

(2012) A. Cesario et al.   CURRENT MEDICINAL CHEMISTRY

Lipocalin2 Promotes Invasion, Tumorigenicity and Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

(2012) Lisa Leung et al.   PLoS One

Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes

(2012) Marco Donia et al.   OncoImmunology

Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival

(2011) Jonathan R. Brody et al.   CELL CYCLE

Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives

(2011) J. Godin-Ethier et al.   CLINICAL CANCER RESEARCH

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

(2011) Christiane A. Opitz et al.   NATURE

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells

(2011) Christiane A. Opitz et al.   PLoS One

TRAIL-R4 Promotes Tumor Growth and Resistance to Apoptosis in Cervical Carcinoma HeLa Cells through AKT

(2011) Najoua Lalaoui et al.   PLoS One

Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion

(2010) Alexander J. Muller et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells

(2010) J. D. Mezrich et al.   JOURNAL OF IMMUNOLOGY

Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma

(2009) Hiroshi Urakawa et al.   CLINICAL & EXPERIMENTAL METASTASIS

Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active Target

(2009) Agnieszka K. Witkiewicz et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma

(2008) Ke Pan et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Expression of Indoleamine 2,3-Dioxygenase in Metastatic Pancreatic Ductal Adenocarcinoma Recruits Regulatory T Cells to Avoid Immune Detection

(2008) Agnes Witkiewicz et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins

(2008) Marc Veldhoen et al.   NATURE

Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor

(2008) Francisco J. Quintana et al.   NATURE